Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Intraocular Lymphoma 1Hodgkin Disease 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Carboplatin 50Paclitaxel 48Cisplatin 39Gemcitabine 31Erlotinib Hydrochloride 30Radiotherapy 28Docetaxel 24Taxes 21Specimen Handling 20Magnetic Resonance Spectroscopy 20Vinorelbine 16Pemetrexed 12Etoposide 12Bevacizumab 12Radiation 10Gefitinib 10aldesleukin 8Platinum 8Bortezomib 8Biopsy 8Vinblastine 7Azacitidine 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6atezolizumab 6Observation 6Immunoglobulin G 6Disulfides 6Cyclophosphamide 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Non-Small-Cell Lung × oblimersen × Clear all
NCT00030641 2014-01-06

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡